Sacubitril/Valsartan in Advanced Heart Failure With Reduced Ejection Fraction: Rationale and Design of the LIFE Trial

The PARADIGM-HF (Prospective Comparison of Angiotensin II Receptor Blocker Neprilysin Inhibitor With Angiotensin-Converting Enzyme Inhibitor to Determine Impact on Global Mortality and Morbidity in Heart Failure) trial reported that sacubitril/valsartan (S/V), an angiotensin receptor-neprilysin inhi...

Full description

Saved in:
Bibliographic Details
Published in:JACC Heart Fail
Main Authors: Mann, Douglas L., Greene, Stephen J., Givertz, Michael M., Vader, Justin M., Starling, Randall C., Ambrosy, Andrew P., Shah, Palak, McNulty, Steven E., Mahr, Claudius, Gupta, Divya, Redfield, Margaret M., Lala, Anuradha, Lewis, Gregory D., Mohammed, Selma F., Gilotra, Nisha A., DeVore, Adam D., Gorodeski, Eiran Z., Desvigne-Nickens, Patrice, Hernandez, Adrian F., Braunwald, Eugene
Format: Artigo
Language:Inglês
Published: by the American College of Cardiology Foundation. Published by Elsevier. 2020
Subjects:
Focus Issue: Angiotensin-Neprilysin Inhibition: Novel Insights
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7286640/
https://ncbi.nlm.nih.gov/pubmed/32641226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jchf.2020.05.005
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items